Skip to content

Author

V. Copeland

We have 6 of 36 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Adverse effect of left ventricular hypertrophy in women with heart failure

Left ventricular hypertrophy is a hallmark of adverse remodeling in heart failure (HF), yet commonly used echocardiographic measures provide limited insight into sex-specific risk. Interventricular septal (IVS) thickness is routinely measured, but its independent prognostic value and potential sex-related differe...

A. Kaplan, V. Copeland, R. Loutati et al. · 0 citations
Open access Oct 2026

Chronic kidney disease in metabolic syndrome and heart failure: elevated risk, underutilized therapies, and missed opportunities for improved outcomes

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder involving heart disease, kidney disease, diabetes, and obesity. Chronic kidney disease (CKD) is highly prevalent in this advanced phenotype, increases mortality risk, and complicates optimal therapy selection. We evaluated mortality, dialysis r...

D. Hochstein, R. Loutati, V. Copeland et al. · 0 citations
Sep 2026

Calcium Channel Blockers are Safe and Beneficial in Patients with Heart Failure and Advanced Chronic Kidney Disease.

In patients with heart failure and advanced chronic kidney disease, CCBs use was associated with improved survival, supporting their potential role as a safe adjunctive therapy for blood pressure control in this high-risk population.

V. Copeland, A. Milwidsky, S. Elimeleh et al. · 0 citations
Open access Sep 2026

Point-of-care echocardiography screening for hypertrophic cardiomyopathy using automated deep-learning analysis

Abstract Aims Hypertrophic cardiomyopathy (HCM) remains underdiagnosed due to limited access to expert imaging. We developed and validated a deep-learning (DL)-based echocardiographic model adaptable to point-of-care ultrasound (POCUS) for scalable HCM screening. Methods and results We retrospectively analysed 134 956...

N. Karra, Y. Klempfner, V. Copeland et al. · 0 citations
Aug 2026

Frailty Attenuates the Prognostic Value of Multimorbidity in Heart Failure - Insights From the Largest Tertiary Center in the Middle East.

Frailty fundamentally attenuates risk in HF, while multimorbidity stratifies prognosis only when physiological reserve is preserved, while multimorbidity stratifies prognosis only when physiological reserve is preserved.

V. Copeland, Boris Fishman, S. Elimeleh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.